Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy

This study has been completed.
Information provided by:
Cytos Biotechnology AG
ClinicalTrials.gov Identifier:
First received: April 1, 2008
Last updated: April 4, 2008
Last verified: April 2008

The purpose of the study is to test the safety, tolerability, immunogenicity and clinical efficacy of the combination treatment AllQbG10 in patients with rhino-conjunctivitis and asthma due to house dust mite allergy in a single-center, open-label setting.

Condition Intervention Phase
Perennial Allergic Rhinoconjunctivitis
Allergic Asthma
Biological: CYT005-AllQbG10
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Safety, Immunogenicity and Clinical Efficacy of an Allergen Vaccine (AllQbG10) in Subjects With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy

Resource links provided by NLM:

Further study details as provided by Cytos Biotechnology AG:

Enrollment: 21
Study Start Date: March 2005
Study Completion Date: November 2005
Arms Assigned Interventions
Experimental: 1 Biological: CYT005-AllQbG10
Immunomodulator CYT003-QbG10 in combination with commercial house dust mite extract as used for routine SIT


Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Mild to moderate perennial allergic rhinoconjunctivitis due to sensitization against house dust mites
  • Mild asthma
  • Females only if non-reproductive or agree to practice an effective and accepted method of contraception

Exclusion Criteria:

  • Relevant cardiovascular, renal, pulmonary or endocrine disease
  • History of autoimmune disease
  • Severe allergies
  • History of active infectious disease
  • Current diagnosis or history of malignancy
  • Relevant neurological or psychiatric disorder
  • Pregnancy or lactation
  • History of alcohol abuse or other recreational drugs
  • Use of an investigational drug within three month before enrolment
  • Blood donation within 30 days before enrolment
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00652223

University Hospital Zurich, Department of Dermatology
Zurich, Switzerland, 8091
Sponsors and Collaborators
Cytos Biotechnology AG
Study Director: Philipp Mueller, MD Cytos Biotechnology AG
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00652223     History of Changes
Other Study ID Numbers: CYT005-AllQbG10 01
Study First Received: April 1, 2008
Last Updated: April 4, 2008
Health Authority: Switzerland: Swissmedic

Additional relevant MeSH terms:
Conjunctivitis, Allergic
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Conjunctival Diseases
Eye Diseases

ClinicalTrials.gov processed this record on April 17, 2014